Undisclosed next-generation selective peptide MC4R agonist / Palatin Technologies - LARVOL DELTA

Obesity Program Update (TradingView) - "Next-generation peptide MC4R selective agonists..Investigational New Drug (IND) submission and initiation of a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial remains on track for the fourth quarter of calendar year 2026...Palatin is advancing next-generation oral small molecule MC4R selective agonist candidates based on data and learnings from earlier compounds, including PL7737, and broader program insights...IND submission and initiation of a Phase 1 SAD/MAD trial for a next-generation oral MC4R selective agonist candidate is targeted for the first half of calendar year 2027."

IND • New P1 trial • Hypothalamic Injury-associated Obesity • Obesity

Obesity Program Update (The Malaysian Reserve) - "PL7737 (oral MC4R agonist)...IND-enabling toxicology studies are progressing as planned, with an IND submission and initiation of a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial anticipated in the first half of 2026; Next-generation selective peptide MC4R agonists: Designed for once-weekly subcutaneous dosing, with an IND submission and initiation of a Phase 1 SAD/MAD trial targeted for the second half of 2026."

IND • New P1 trial • Hypothalamic Injury-associated Obesity • Obesity